GU (Genitourinary)

NRG – GU011 at https://clinicaltrials.gov/study/NCT05053152
A Phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN)

Cancer Type: Adenocarcinoma of the prostate

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – GU013 at https://clinicaltrials.gov/study/NCT05946213

The Phase III ‘High Five Trial’ Five Fraction radiation for High-Risk Prostate Cancer

Cancer Type: High-Risk Prostate Cancer

Principal Investigator: Dr. Nathan Tennyson

Please contact Clinical Trials Office for more details: 561-263-5791

GU (Genitourinary)

NRG – GU010 at Study Details | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | ClinicalTrials.gov

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Cancer Type: Unfavorable intermediate risk prostate cancer, Adenocarcinoma

Principal Investigator: Dr. Nathan Tennyson

Please contact Clinical Trials Office for more details: 561-263-5791